$5.11
1.39%
Nasdaq, Sep 02, 10:16 pm CET
ISIN
US74587V1070
Symbol
PBYI

Puma Biotechnology, Inc. Stock price

$5.11
+1.93 60.69% 1M
+1.76 52.54% 6M
+2.06 67.54% YTD
+2.61 104.40% 1Y
+2.53 98.06% 3Y
-4.76 48.23% 5Y
-89.33 94.59% 10Y
-8.39 62.15% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.07 1.39%
ISIN
US74587V1070
Symbol
PBYI
Industry

Key metrics

Basic
Market capitalization
$257.4m
Enterprise Value
$206.2m
Net debt
positive
Cash
$96.0m
Shares outstanding
49.9m
Valuation (TTM | estimate)
P/E
5.2 | 10.1
P/S
1.1 | 1.2
EV/Sales
0.9 | 0.9
EV/FCF
4.7
P/B
2.5
Financial Health
Equity Ratio
43.2%
Return on Equity
32.9%
ROCE
39.8%
ROIC
58.7%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$238.1m | $220.8m
EBITDA
$57.3m | $40.8m
EBIT
$46.1m | $25.8m
Net Income
$48.5m | $25.2m
Free Cash Flow
$44.2m
Growth (TTM | estimate)
Revenue
8.6% | -4.2%
EBITDA
88.1% | -4.0%
EBIT
143.6% | -16.6%
Net Income
455.6% | -16.9%
Free Cash Flow
33.0%
Margin (TTM | estimate)
Gross
72.3%
EBITDA
24.1% | 18.5%
EBIT
19.4%
Net
20.4% | 11.4%
Free Cash Flow
18.6%
More
EPS
$1.0
FCF per Share
$0.9
Short interest
6.2%
Employees
172
Rev per Employee
$1.3m
Show more

Is Puma Biotechnology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Puma Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Puma Biotechnology, Inc. forecast:

1x Buy
13%
3x Hold
38%
4x Sell
50%

Analyst Opinions

8 Analysts have issued a Puma Biotechnology, Inc. forecast:

Buy
13%
Hold
38%
Sell
50%

Financial data from Puma Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
238 238
9% 9%
100%
- Direct Costs 66 66
12% 12%
28%
172 172
8% 8%
72%
- Selling and Administrative Expenses 69 69
22% 22%
29%
- Research and Development Expense 57 57
11% 11%
24%
57 57
88% 88%
24%
- Depreciation and Amortization 11 11
3% 3%
5%
EBIT (Operating Income) EBIT 46 46
144% 144%
19%
Net Profit 48 48
456% 456%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Puma Biotechnology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Puma Biotechnology, Inc. Stock News

Neutral
Business Wire
about 13 hours ago
LOS ANGELES--(BUSINESS WIRE)--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.
Neutral
Business Wire
26 days ago
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the issuance of inducement awards to three new hires, as required under Nasdaq Listing Rule 5635(c)(4).
Neutral
The Motley Fool
26 days ago
Puma (PBYI) Q2 Revenue Rises 11%
More Puma Biotechnology, Inc. News

Company Profile

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Head office United States
CEO Alan Auerbach
Employees 172
Founded 2010
Website www.pumabiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today